Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Erasca, Inc.

Market Cap 4.37B 3.77B 3.48B 3.26B 6.1B 415B 6.19B 41.06B 16.01B 202B 16.4B 16.05B 700B P/E Ratio 2026 *
-14.6x
P/E Ratio 2027 * -24.9x
Enterprise Value 3.7B 3.19B 2.94B 2.75B 5.16B 351B 5.24B 34.75B 13.55B 171B 13.88B 13.58B 592B EV / Sales 2026 *
-
EV / Sales 2027 * 7,297x
Free-Float
89.34%
Yield 2026 *
-
Yield 2027 * -
1 day+0.29%
1 week+17.38%
Current month+9.42%
1 month+34.32%
3 months+3.16%
6 months+290.28%
Current year+277.69%
1 week 12.26
Extreme 12.26
14.6
1 month 9.95
Extreme 9.95
15.03
Current year 3.36
Extreme 3.36
24.28
1 year 1.21
Extreme 1.21
24.28
3 years 1.01
Extreme 1.01
24.28
5 years 1.01
Extreme 1.01
24.47
10 years 1.01
Extreme 1.01
24.47
Manager TitleAgeSince
Chief Executive Officer 54 2019-02-28
Director of Finance/CFO 43 2021-01-06
Chief Tech/Sci/R&D Officer - 2022-05-24
Director TitleAgeSince
Chairman 54 2018-09-30
Director/Board Member 79 2018-05-31
Director/Board Member 58 2018-07-01
Date Insider Type Main position Quantity % Market Cap.
03-31Fiscal year

General Counsel

240,000 0.0772%
03-03Fiscal year

Chief Technology Officer

60,000 0.0194%
01-28Free

Chief Executive Officer

2,000,000 0.7049%
Change 5-day change 1-year change 3-year change Capi.($)
+0.29%+17.38%+849.32%+379.52% 4.37B
-0.35%+0.97%-13.80%-13.25% 43.03B
+3.11%+3.11%+279.08%+501.52% 32.71B
+0.22%-1.08%+15.66%-15.65% 30.29B
+1.62%-2.08%-1.91%+24.64% 29.4B
+4.09%+0.93%+12.97%+20.22% 25.08B
+1.14%+3.62% - - 13.54B
-1.63%+2.88%+56.69%+113.41% 13.35B
-0.40%-1.29%+6.23%+7.63% 12.97B
-0.74%-1.62%+105.89%+74.92% 12.11B
Average +0.74%+3.04%+145.57%+121.44% 21.68B
Weighted average by Cap. +1.03%+1.80%+74.32%+102.17%

Financials

2026 *2027 *
Net sales - 500K 432K 398K 372K 698K 47.53M 709K 4.7M 1.83M 23.13M 1.88M 1.84M 80.1M
Net income -299M -258M -238M -222M -417M -28.38B -423M -2.81B -1.09B -13.81B -1.12B -1.1B -47.83B -189M -164M -151M -141M -264M -18B -268M -1.78B -694M -8.76B -711M -696M -30.33B
Net Debt -672M -580M -535M -500M -938M -63.85B -952M -6.31B -2.46B -31.08B -2.52B -2.47B -108B -721M -622M -574M -537M -1.01B -68.5B -1.02B -6.77B -2.64B -33.34B -2.7B -2.65B -115B
Logo Erasca, Inc.
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
Employees
103
Date Price Change Volume
26-06-12 14.05 $ +0.29% 2,078,145
26-06-11 14.01 $ +4.79% 5,704,057
26-06-10 13.37 $ -0.30% 3,655,689
26-06-09 13.41 $ +4.20% 4,650,851
26-06-08 12.87 $ +7.52% 5,856,712
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
14.05USD
Average target price
21.00USD
Spread / Average Target
+49.47%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ERAS Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!